Abeona Therapeutics CFO Joseph Vazzano sells $47,385 in company stock

Chief Financial Officer Joseph Vazzano of Abeona Therapeutics sold 9,191 shares of company stock worth around $47,385 on September 29, 2026, as per an SEC filing. The sale, conducted in multiple trades at prices between $5.1150 and $5.3000 per share, was to cover tax liabilities associated with the vesting of restricted stock awards.

This transaction, following a 6.7% decline in the company's stock price over the past week, left Vazzano holding 482,888 shares of Abeona Therapeutics common stock. Analysts assess the stock as undervalued, with InvestingPro rating it as such. Abeona Therapeutics reported Q2 2026 earnings, showing a 31% revenue increase for its lead therapy ZEVASKYN, reaching $11.4 million, though below analyst expectations of $12.24 million.

The company reported a net loss of $20.2 million. Positive developments include the FDA approval of FAYUVI, a gene therapy, for Sanfilippo syndrome type A, leading to an upgrade of Abeona's stock rating by H.C. Wainwright and Cantor Fitzgerald. Roth/MKM also initiated coverage with a Buy rating. These updates highlight both financial challenges and advancements for Abeona Therapeutics.